Viabilidade da Cannabis no tratamento de Alzheimer
DOI:
https://doi.org/10.61223/coopex.v14i4.417Palavras-chave:
Terapêutica; mal de Alzheimer; Demência do tipo Alzheimer; Canabidiol.Resumo
Introdução: No mundo, em média, 50 milhões de pessoas possuem algum tipo de demência. Idade, genética, doenças cardiovasculares e traumatismo craniano são fatores de risco para o seu desenvolvimento. Visto o aumento dos casos de demência do tipo Alzheimer, a utilização de substâncias como a Cannabis para o tratamento da patologia torna-se cada vez mais discutida no âmbito médico, surgindo como terapia inovadora. Objetivo: Compreender a viabilidade da utilização da cannabis como tratamento inovador para a Doença de Alzheimer. Metodologia: Trata-se de uma revisão integrativa, triados estudos dos bancos de dados da Scientific Electronic Library Online, Biblioteca Virtual em Saúde e Biblioteca nacional de medicina dos Estados Unidos, seguindo os critérios de exclusão e inclusão determinado, em que foram selecionados 26 artigos, para compor a amostragem final. Resultados: A maior parte dos estudos mostrou que a Cannabis é efetiva até certo ponto no tratamento de sintomas associados, porém, há necessidade de mais estudos para entender melhor a ação da planta e seus possíveis efeitos colaterais (80,7%). Conclusão: Os dados mostram a efetividade da cannabis como uma substância inovadora para o tratamento do Alzheimer, porém ainda são necessárias mais pesquisas para esclarecer os benefícios e malefícios no seu uso, além de sua segurança.
Referências
ABATE, Giulia; UBERTI, Daniela; TAMBARO, Simone. Potential and Limits of Cannabinoids in
Alzheimer's Disease Therapy. Biology, 24 maio 2023.
ABYADEH, Morteza et al. A Proteomic View of Cellular and Molecular Effects of Cannabis.
Biomolecules, v. 11, p. ., 27 set. 2021. Disponível em: www.mdpi.com/2218-273X/11/10/1411. Acesso
em: 24 maio 2023.
ALZHEIMER'S DISEASE INTERNATIONAL. The global impact of dementia: an analysis of
prevalence, incidence, cost and trends. An analysis of prevalence, incidence, cost and trends. 2015.
Disponível em: https://www.alzint.org/resource/world-alzheimer-report-2015/. Acesso em: 30 maio
BENITO, Cristina et al. Cannabinoid CB2 Receptors and Fatty Acid Amide Hydrolase Are Selectively
Overexpressed in Neuritic Plaque-Associated Glia in Alzheimer‘s Disease Brains. Journal of
Neuroscience, v. 23, 3 dez. 2003. Disponível em: https://www.jneurosci.org/content/23/35. Acesso em:
maio 2023.
BHUNIA, Sukanya et al. Cannabidiol for neurodegenerative disorders: A comprehensive review. Front.
Pharmacol, v. 13, 25 out. 2022. Disponível em:
https://www.frontiersin.org/articles/10.3389/fphar.2022.989717/full. Acesso em: 24 maio 2023.
BITTES, Yara Paiva et al. Uso dos canabinóides no tratamento de pessoas portadoras de alzheimer.
REVISA, v. 10, 17 set. 2021. DOI https://doi.org/10.36239/revisa.v10.nEsp2.p887a899.
BONINI, Sara et al. Cannabis sativa: A comprehensive ethnopharmacological review of a medicinal
plant with a long history. Journal of Ethnopharmacology, v. 227, p. 300-315, 5 dez. 2018. Disponível
em: https://www.sciencedirect.com/science/article/abs/pii/S0378874118316611?via%3Dihub. Acesso
em: 24 maio 2023.
Hallysson André de Oliveira Medeiros et al.
http://coopex.unifip.edu.br (ISSN:2177-5052), v. 14, n.04. 3130-3143p 2023
CAMPOS, Alline et al. Cannabidiol, neuroprotection and neuropsychiatric disorders. Pharmacological
Research, p. 119-127, 1 out. 2016. Disponível em:
https://www.sciencedirect.com/science/article/abs/pii/S1043661816000396?via%3Dihub. Acesso em:
maio 2023.
CASSANO, Tommaso et al. From Cannabis sativa to Cannabidiol: Promising Therapeutic Candidate
for the Treatment of Neurodegenerative Diseases. Front. Pharmacol, v. 11, p. 6 mar. 2022. Disponível
em: https://www.frontiersin.org/articles/10.3389/fphar.2020.00124/full. Acesso em: 24 maio 2023.
COLES, Madilyn; STEINER-LIM, Genevieve Z.; KARL, Tim. Therapeutic properties of multicannabinoid treatment strategies for Alzheimer’s disease. Frontiers Neuroscience, v. 16, 2 set. 2022.
DOI 10.3389/fnins.2022.962922
COORAY, R.; GUPTA, V.; SUPHIOGLU, C. Current Aspects of the Endocannabinoid System and
Targeted THC and CBD Phytocannabinoids as Potential Therapeutics for Parkinson's and Alzheimer's
Diseases: a Review. Molecular Neurobiology, p. 4878-4890, 19 ago. 2020.
CROCQ, Marc-Antoine. History of cannabis and the endocannabinoid system. Dialogues in Clinical
Neuroscience, p. 223-228, 1 abr. 2022.
CUMMINGS, Jeffrey; TONG, Gary; BALLARD, Clive. Treatment Combinations for Alzheimer’s
Disease: Current and Future Pharmacotherapy Options. Journal of Alzheimer‘s Disease, v. 67, p. 779-
, 12 fev. 2019. Disponível em: https://content.iospress.com/articles/journal-of-alzheimersdisease/jad180766. Acesso em: 24 maio 2023.
EUBANKS, Lisa M. et al. A Molecular Link between the Active Component of Marijuana and
Alzheimer‘s Disease Pathology. Molecular Pharmaceutics, p. 773-777, 9 ago. 2006.
FOSSATTI, Emanuele Canali; MOZZATO, Anelise Rebelato; MORETTO, Cleide Fátima. O uso da
revisão integrativa na administração: um método possível?. Revista eletrônica Científica do CRA-PR,
Passo Fundo, ano 2019, v. 6, n. 1, p. 55-72, 7 jul. 2019.
FRAGOSO, Yara; CARRA, Adriana; MACIAS, Miguel. Cannabis and multiple sclerosis. Expert
Review of Neurotherapeutics, v. 20, p. 849-854, 18 jun. 2020. Disponível em:
https://www.tandfonline.com/doi/abs/10.1080/14737175.2020.1776610?journalCode=iern20. Acesso
em: 24 maio 2023.
GHASEMIESFE, Mehrnaz et al. Association Between Marijuana Use and Risk of Cancer: A Systematic
Review and Meta-analysis. JAMA Netw Open, 27 nov. 2019.
HERRMANN, Nathan et al. Randomized Placebo-Controlled Trial of Nabilone for Agitation in
Alzheimer's Disease. The American Journal Of Geriatric Psychiatry, v. 27, n. 11, p. 1161-1173, 8
maio 2019. http://dx.doi.org/10.1016/j.jagp.2019.05.002.
KASKIE, Brian et al. Cannabis Use among Persons with Dementia and Their Caregivers: Lighting up
an Emerging Issue for Clinical Gerontologists. Clinical Gerontologist, v. 44, p. 42-52, 29 nov. 2020.
Disponível em: https://www.tandfonline.com/doi/full/10.1080/07317115.2020.1852465. Acesso em: 24
maio 2023.
Viabilidade da Cannabis no tratamento de Alzheimer
KIM, Seok Hee et al. A Review on Studies of Marijuana for Alzheimer’s Disease – Focusing on CBD,
THC. Journal of Pharmacopuncture, p. 225-230, 31 dez. 2019.
KUHARIC, Dina Bosnjak et al. Cannabinoids for the treatment of dementia. Cochrane Database Syst
Rev. 17 set. 2021.
LAWS, John Staton; SMID, Scott D.. Evaluating Cannabis sativa L.’s neuroprotection potential: from
bench to bedside. Phytomedicine, v. 107, 29 set. 2022.
http://dx.doi.org/10.1016/j.phymed.2022.154485.
LESZKO, Magdalena; MEENRAJAN, Senthil. Attitudes, beliefs, and changing trends of cannabidiol
(CBD) oil use among caregivers of individuals with Alzheimer’s disease. Complementary Therapies
in Medicine, v. 57, 1 mar. 2021. Disponível em:
https://www.sciencedirect.com/science/article/pii/S0965229921000017?via%3Dihub. Acesso em: 24
maio 2023.
LEVY, Cari; GALENBECK, Emily; MAGID, Kate. Cannabis for Symptom Management in Older
Adults. Medical Clinics of North America, v. 104, n. 3, p. 471-489, 17 abr. 2020.
LIMEIRA, R. B. P.; NOGUEIRA, R. B. S. S.; SOUSA, M. N. A. O uso da cannabis sativa no
tratamento da doença de alzheimer. Acadêmico Mundo, v.9, p.1 - 18, 2021.
OLIVEIRA, Bruna Stefane Alves de et al. The gut microbiota in neurodegenerative diseases: revisiting
possible therapeutic targets for cannabidiol. Heliyon, v. 8, n. 12, 8 dez. 2022.
OZAROWSKI, Marcin et al. Cannabidiol in Neurological and Neoplastic Diseases: Latest
Developments on the Molecular Mechanism of Action. Internacional Journal of Molecular Sciences,
abr. 2021.
PAES-COLLI, Yolanda et al. Phytocannabinoids and Cannabis-Based Products as Alternative
Pharmacotherapy in Neurodegenerative Diseases: From Hypothesis to Clinical Practice. Front. Cell.
Neurosci, [S. l.], v. 16, p. ., 30 maio 2022. Disponível em:
https://www.frontiersin.org/articles/10.3389/fncel.2022.917164/full. Acesso em: 24 maio 2023.
PALMIERI, B.; VADALÀ, M.. Oral thc: cbd cannabis extract in main symptoms of alzheimer disease.
La Clinica Terapeutica, v. 174, n. 1, p. 53-60, 20 jan. 2023.
https://pubmed.ncbi.nlm.nih.gov/36655645/. Acesso em: 26 maio 2023.
PAZOS, M.R. et al. Role of the endocannabinoid system in Alzheimer‘s disease: New perspectives.
Life Sciences, [S. l.], v. 75, p. 1907-1915, 3 set. 2004.
PEPRAH, Kwakye; MCCORMACK, Suzanne. Medical Cannabis for the Treatment of Dementia: A
Review of Clinical Effectiveness and Guidelines [Internet]. Canadian Agency for Drugs and
Technologies in Health, Ottawa, 17 jul. 2019. Disponível em:
https://www.ncbi.nlm.nih.gov/books/NBK546328/. Acesso em: 26 maio 2023.
PLANCARTE-SÁNCHEZ, Ricardo et al. Therapeutic applications based on cannabinoids action.
Gaceta Médica de México, [S.L.], v. 155, n. 3, p. 307-318, 28 mar. 2019. Publicidad Permanyer, SLU.
Hallysson André de Oliveira Medeiros et al.
http://coopex.unifip.edu.br (ISSN:2177-5052), v. 14, n.04. 3130-3143p 2023
http://dx.doi.org/10.24875/gmm.18004928. Disponível em:
https://www.gacetamedicademexico.com/frame_esp.php?id=310. Acesso em: 26 maio 2023.
RAMESH, D. et al. Marijuana Dependence: not just smoke and mirrors. Ilar Journal, v. 52, n. 3, p.
-308, 1 dez. 2011. Oxford University Press (OUP). http://dx.doi.org/10.1093/ilar.52.3.295.
Disponível em: https://academic.oup.com/ilarjournal/article/52/3/295/755648?login=false. Acesso em:
maio 2023.
RAMÍREZ, Belén et al. Prevention of Alzheimer‘s Disease Pathology by Cannabinoids:
Neuroprotection Mediated by Blockade of Microglial Activation. Journal of Neuroscience, v. 25, p.
-1913, 23 fev. 2005. Disponível em: https://www.jneurosci.org/content/25/8/1904.long. Acesso em:
maio 2023.
REDDY, Vamsi et al. Targeting the endocannabinoid system: a predictive, preventive, and personalized
medicine-directed approach to the management of brain pathologies. EPMA Journal, p. 217-250, 15
abr. 2020.
REZKALLA, Shereif; KLONER, Robert A. Cardiovascular effects of marijuana. Trends in
Cardiovascular Medicine, p. 403-407, 13 ago. 2019.
RUVER-MARTINS, Ana Carolina et al. Cannabinoid extract in microdoses ameliorates mnemonic and
nonmnemonic Alzheimer’s disease symptoms: a case report. Journal Of Medical Case Reports, v. 16,
n. 1, 12 jul. 2022. Springer Science and Business Media LLC. http://dx.doi.org/10.1186/s13256-022-
-w.
SANTOS, P. H. C. C. et al. Manejo do Alzheimer a partir da terapia ocupacional. Revista Brasileira de
Filosofia e História, v.11, p. 209 - 218, 2022.
SCHUBERT, David et al. Efficacy of Cannabinoids in a Pre-Clinical Drug-Screening Platform for
Alzheimer's Disease. Molecular Neurobiology, p. 7719-7730, 19 maio 2019.
SELKOE, Dennis; HARDY, John. The amyloid hypothesis of Alzheimer‘s disease at 25 years. EMBO
Mol Med., v. 8, p. 595-608, 1 jun. 2016. Disponível em:
https://www.embopress.org/doi/full/10.15252/emmm.201606210. Acesso em: 24 maio 2023.
SHADE, Ronnie D.; ROSS, Jennifer A.; BOCKSTAELE, Elisabeth J. Van. Targeting the cannabinoid
system to counteract the deleterious effects of stress in Alzheimer’s disease. Frontiers in Aging
Neuroscience, 4 out. 2022. DOI 10.3389/fnagi.2022.949361.
SHELEF, Assaf et al. Safety and Efficacy of Medical Cannabis Oil for Behavioral and Psychological
Symptoms of Dementia: an-open label, add-on, pilot study. Journal Of Alzheimer'S Disease, v. 51, n.
, p. 15-19, 27 fev. 2016.
SILVA, Roni Robson da et al. Therapeutic use of medicinal cannabis in people with degenerative
neurological disease. Revista de Pesquisa Cuidado É Fundamental Online, [S.L.], v. 14, p. 1-8, 30
set. 2022.
TIMLER, Amanda et al. Use of cannabinoid-based medicine among older residential care recipients
diagnosed with dementia: study protocol for a double-blind randomised crossover trial. Trials, Nova
Zelândia, ano 2020, v. 21, n. 188, p. -, 14 fev. 2020.
Viabilidade da Cannabis no tratamento de Alzheimer
VOLKOW , Nora D. et al. Adverse health effects of marijuana use. The New England Journal of
Medicine, p. 2219-2227, 5 jun. 2014.
YOUSAF, Muhammad et al. Neuroprotection of Cannabidiol, Its Synthetic Derivatives and
Combination Preparations against Microglia-Mediated Neuroinflammation in Neurological Disorders.
Molecules, 4 ago. 2022.
ZERAATKAR, Dena et al. Long-term and serious harms of medical cannabis and cannabinoids for
chronic pain: a systematic review of non-randomised studies. BMJ Open, v. 12, n. 8, p. 0-0, 4 ago.
Downloads
Publicado
Como Citar
Licença
Copyright (c) 2023 Hallysson André de Oliveira Medeiros, Ana Luiza de Sousa Oliveira , Caio Saraiva de Freitas Figueiredo, Caio Lustosa Trindade, Caio Lustosa Trindade, Milena Nunes Alves de Sousa
Este trabalho está licenciado sob uma licença Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Creative Commons 
.png){kind=logo}
